Zejula (Niraparib) 100mg – Niranib Generic
Zejula (Niraparib) 100mg, available in its generic form Niranib, is an advanced oral PARP inhibitor used for the maintenance treatment of ovarian, fallopian tube, and primary peritoneal cancers. Manufactured by Everest Pharmaceuticals Ltd., Bangladesh, this therapy is recommended for patients who have shown a complete or partial response to platinum-based chemotherapy. It is a trusted maintenance option due to its effectiveness in both BRCA-mutated and non-BRCA cancers.
How Niraparib Works
Niraparib selectively inhibits PARP-1 and PARP-2 enzymes. These enzymes are crucial for repairing damaged DNA in cancer cells. By blocking this repair mechanism, Niraparib causes cancer cells to accumulate DNA damage, leading to cell death and reduced tumor growth. This targeted mechanism helps prolong progression-free survival in patients with recurrent or advanced gynecologic cancers.
Indications
Zejula (Niranib) is prescribed for:
-
Maintenance therapy in epithelial ovarian cancer
-
Fallopian tube cancer treatment continuation
-
Primary peritoneal cancer following platinum-based chemotherapy
-
Recurrent cancer cases sensitive to platinum therapy
This medicine supports long-term control and reduces the likelihood of cancer recurrence.
Dosage & Administration
-
Standard dose: 300 mg once daily (typically 3 tablets of Niranib 100mg)
-
Dose adjustment may be required based on body weight, platelet count, or tolerability
-
Can be taken with or without food
-
Swallow tablets whole, without crushing or chewing
-
Continue treatment until disease progression or unacceptable toxicity occurs
Patients must follow the oncologist’s guidance for safe and effective results.
Side Effects
Common side effects include:
-
Nausea, vomiting
-
Fatigue or weakness
-
Constipation
-
Loss of appetite
-
Headache
-
Abdominal pain
-
Anemia or low platelet count
-
High blood pressure
Immediate medical attention is required for severe fatigue, shortness of breath, unusual bleeding, or persistent symptoms.
Pregnancy & Lactation
-
Not recommended during pregnancy due to possible fetal harm
-
Effective contraception must be used during treatment
-
Breastfeeding is discouraged during therapy and for at least 1 month after the final dose
Precautions & Warnings
-
Regular blood tests (CBC) are required to monitor platelet and hemoglobin levels
-
Blood pressure should be checked weekly for the first 2 months
-
Use cautiously in patients with liver or kidney impairment
-
Avoid alcohol and self-medication
-
Report any symptoms such as dizziness, bleeding, chest pain, or rapid heartbeat
Drug Interactions
No significant drug interaction studies have been completed.
However, patients should inform healthcare providers about all medicines, supplements, herbal products, or blood pressure medications being taken.
Contraindications
-
Known hypersensitivity to Niraparib
-
Pregnancy or breastfeeding
-
Severe uncontrolled hypertension
Therapeutic Class
PARP Inhibitor – Targeted Anticancer Therapy.
Storage Conditions
-
Store below 25°C, in a cool and dry place
-
Protect from moisture and direct sunlight
-
Keep out of reach of children
